» Articles » PMID: 16313339

Role of RANKL in Physiological and Pathological Bone Resorption and Therapeutics Targeting the RANKL-RANK Signaling System

Overview
Journal Immunol Rev
Date 2005 Nov 30
PMID 16313339
Citations 127
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoclasts are primary cells for physiological and pathological bone resorption, and receptor activator of nuclear factor-kappaB ligand (RANKL) is critically involved in the differentiation, activation, and survival of these cells. Recently, therapeutics for pathological bone destruction targeting RANKL pathways has attracted a great deal of attention. Herein, we review the recent advances in the research on osteoclast biology and discuss the advantages and disadvantages of anti-RANKL therapies.

Citing Articles

Stephanine Protects Against Osteoporosis by Suppressing Osteoclastogenesis via Inhibition of the RANKL-RANK Interaction.

Liu T, Li J, Duan M, Wang Y, Jiang Z, Gan C J Cell Mol Med. 2024; 28(23):e70256.

PMID: 39636143 PMC: 11619157. DOI: 10.1111/jcmm.70256.


A Machine Learning Framework for Screening Plasma Cell-Associated Feature Genes to Estimate Osteoporosis Risk and Treatment Vulnerability.

Wang S, Zhu J, Liu W, Liu A Biochem Genet. 2024; .

PMID: 38898268 DOI: 10.1007/s10528-024-10861-y.


Cinnamaldehyde attenuates streptozocin-induced diabetic osteoporosis in a rat model by modulating netrin-1/DCC-UNC5B signal transduction.

Ji S, Zhao B, Gao Y, Xie J, Han H, Wu Q Front Pharmacol. 2024; 15:1367806.

PMID: 38628640 PMC: 11019308. DOI: 10.3389/fphar.2024.1367806.


Effect of Extract on Osteoclastogenesis In Vitro and In Vivo.

Cho S, Kim H, Ahn J, Ryu B, Jea J, Lee K Mar Drugs. 2024; 22(3).

PMID: 38535478 PMC: 10971717. DOI: 10.3390/md22030137.


Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss.

Xie X, Cheng P, Hu L, Zhou W, Zhang D, Knoedler S Signal Transduct Target Ther. 2024; 9(1):24.

PMID: 38246920 PMC: 10800355. DOI: 10.1038/s41392-023-01726-8.